Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

This Enzyme Appears to Predict RCC Death Risk

J Clin Oncol; 2017 Nov 10; Ho, Kapur, et al

A specific enzyme appears to predict renal cell carcinoma death risk better than existing methods, according to an analysis involving nearly 2,000 individuals. It seems to be particularly accurate in low- and intermediate-risk tumors. Investigators looked at the impact tumor-based enhancer of zeste homolog 2 (EZH2) gene and protein expression had on overall survival in participants from 3 cohorts. Among the results:

  • Patients from the Cancer Genome Atlas with EZH2-high gene expression were 50% more likely to experience overall death than those with low expression.
  • Overall death risk in the University of Texas Southwestern Medical Center cohort was twice as high as those with low expression.
  • It was 40% higher in the Mayo Clinic cohort.
  • Patients in the Mayo group with EZH2-high protein expression were twice as likely to experience RCC-specific death.
  • EZH2 protein expression was particularly prognostic in patients with low-risk tumors.

Citation:

Ho T, Kapur P, Eckel-Passow J, et al. Multicenter validation of enhancer of zeste homolog 2 expression as an independent prognostic marker in localized clear cell renal cell carcinoma. J Clin Oncol. 2017;35(32):3706-3713. doi:10.1200/JCO.2017.73.3238.

This Week's Must Reads

Liquid biopsy aids assessment in advanced imatinib-resistant GIST, George S et al. ASCO 2018. Abstract 11511.

Rapid therapy changes fall short for metastatic GIST, Serrano-Garcia C et al. ASCO 2018, Abstract 11510.

Estimated conditional OS shows upfront TKI benefit in mRCC, Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030

Indolent course found in rare clear cell papillary RCC , Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005

Must Reads in Renal Cell Carcinoma

Estimated conditional OS shows upfront TKI benefit in mRCC, Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030

Indolent course found in rare clear cell papillary RCC , Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005

Study: Clear cell papillary RCC has indolent course, Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005

Some ccRCC subtypes associated with CT features, Bowen L, Xiaojing L. Acad Radiol. 2018 Jul 29. doi: 10.1016/j.acra.2018.05.002

GAG measurements offer prognostic info for RCC, Gatto F et al. Eur Urol Oncol. 2018 Jun 13. doi: 10.1016/j.euo.2018.04.015